Scientists have mapped every connection in the brain and nerve cord of an adult male animal, unlocking insights into the neural mechanisms that shape behaviour. Known in scientific terms as a ‘connectome’, the team have produced a wiring map of the 166,700 neurons and the millions of connections between them. Read More
DDW Editor Reece Armstrong speaks to Joel Stanley, CEO of Ajna BioSciences, about the challenges of developing therapies for autism and… Read More
The latest issue of Drug Discovery World is out now. The DDW Summer 2026 issue examines the multi-compound approach to autism, the outlook for GLP-1 therapies and highlights drug discovery innovators and Investors – investment challenges and opportunities for drug developers. It also included features on: The importance of tech and collaboration for immunotherapies The… Read More
The US Food and Drug Administration (FDA) has granted Fast Track designation to SPG601 for the treatment of people with Fragile X syndrome (FXS). FXS, a known cause of autism, is the leading inherited form of intellectual disability that can produce a wide range of disabling symptoms,… Read More
News round-up for 1-5 April by DDW Digital Content Editor Diana Spencer. This has been a busy week in the field of neuroscience drug discovery, with EU approval for a long-acting schizophrenia treatment, research revealing new insights into autism, the formation of a partnership focused on ALS drug… Read More
An analysis of how brains with different forms of autism develop has revealed common underlying mechanisms that may respond to existing medications. For the study, Rutgers Health researchers used induced pluripotent stem cells to transform the blood cells of people with both genetic and idiopathic autism… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon,… Read More
News round-up for 11-15 March by DDW Digital Content Editor Diana Spencer. Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon, Portugal, there have been a number of key announcements regarding investigational therapies for neurological disorders, particularly Alzheimer’s disease and Parkinson’s disease. Read More
Robust efficacy in several preclinical models supports high translational potential of zelquistinel in autism and reflects broader opportunity across synaptic dysfunction disorders. Gate Neurosciences has announced the publication of new peer-reviewed research demonstrating the therapeutic potential of zelquistinel (GATE-251) to address symptoms of autism spectrum disorder… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have heard about a number of studies that demonstrate an inventive… Read More
News round-up for 26-30 June by DDW Digital Content Editor Diana Spencer. This week we have heard about a number of studies that demonstrate an inventive solution to an old problem, either through the use of an original approach or new, advanced technology. Whether… Read More
A new study has revealed consistent biological signals in the human microbiome and other physiological signals associated with autism. The research highlights the need for long-term studies to determine autism’s underlying causes. Taking a new computational approach to the problem, a study published in… Read More
